Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial GlobeNewswire - Mon May 5, 6:00AM CDT

APTO : 1.7100 (-45.71%)
APS.TO : 2.01 (-4.29%)
Aptose Announces Auditor Not Standing for Re-Appointment GlobeNewswire - Wed Apr 23, 4:00PM CDT

APTO : 1.7100 (-45.71%)
APS.TO : 2.01 (-4.29%)
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference GlobeNewswire - Wed Apr 23, 6:30AM CDT

APTO : 1.7100 (-45.71%)
APS.TO : 2.01 (-4.29%)
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025 GlobeNewswire - Tue Apr 1, 7:30AM CDT

APTO : 1.7100 (-45.71%)
APS.TO : 2.01 (-4.29%)
Aptose Reports Year End 2024 Results and Corporate Highlights GlobeNewswire - Fri Mar 28, 7:01AM CDT

APTO : 1.7100 (-45.71%)
APS.TO : 2.01 (-4.29%)
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance GlobeNewswire - Mon Mar 17, 6:30AM CDT

APTO : 1.7100 (-45.71%)
APS.TO : 2.01 (-4.29%)
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort GlobeNewswire - Thu Feb 20, 6:32AM CST

APTO : 1.7100 (-45.71%)
APS.TO : 2.01 (-4.29%)
Aptose Announces Reverse Share Split GlobeNewswire - Tue Feb 18, 3:30PM CST

APTO : 1.7100 (-45.71%)
APS.TO : 2.01 (-4.29%)
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility GlobeNewswire - Thu Feb 13, 3:30PM CST

APTO : 1.7100 (-45.71%)
APS.TO : 2.01 (-4.29%)
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial GlobeNewswire - Wed Feb 12, 6:00AM CST

APTO : 1.7100 (-45.71%)
APS.TO : 2.01 (-4.29%)

Barchart Exclusives

This Dividend-Yielding Tech Stock Looks a ‘Compelling Buy’ for 2026 After 2 Years of Underperformance Barchart - Wed Dec 24, 6:30PM CST
Microsoft is set to underperform markets for the second consecutive year. Dan Ives of Wedbush, meanwhile, sees it as a “compelling” buy and predicts nearly 30% upside next year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot